Venus Concept Inc. (VERO)

NASDAQ: VERO · IEX Real-Time Price · USD
0.356
+0.005 (1.37%)
Jan 27, 2023, 3:59 PM EST - Market closed
1.37%
Market Cap 24.67M
Revenue (ttm) 107.85M
Net Income (ttm) -38.12M
Shares Out 69.33M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 250,104
Open 0.360
Previous Close 0.351
Day's Range 0.350 - 0.374
52-Week Range 0.150 - 1.690
Beta 0.90
Analysts Buy
Price Target 2.21 (+520.96%)
Earnings Date Mar 27, 2023

About VERO

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional ... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Domenic Serafino
Employees 407
Stock Exchange NASDAQ
Ticker Symbol VERO
Full Company Profile

Financial Performance

In 2021, Venus Concept's revenue was $105.62 million, an increase of 35.39% compared to the previous year's $78.01 million. Losses were -$23.01 million, -74.09% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VERO stock is "Buy." The 12-month stock price forecast is $2.21, which is an increase of 520.96% from the latest price.

Price Target
$2.21
(520.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Venus Concept (VERO) Stock Up 81% Today?

Venus Concept (NASDAQ: VERO) stock is rocketing higher on Wednesday following approval for its fractional skin resurfacing technology. The U.S. Food and Drug Administration (FDA) has signed off on th...

1 month ago - InvestorPlace

Why Venus Concept (VERO) Shares Are Trading Higher Premarket Today?

Venus Concept Inc has received an FDA 510(k) clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing.

1 month ago - Benzinga

Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug ...

1 month ago - GlobeNewsWire

Venus Concept Announces Completion of $6.72 Million Private Placement Financing

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has completed a n...

2 months ago - GlobeNewsWire

Venus Concept Announces Third Quarter of Fiscal Year 2022 Financial Results

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three...

2 months ago - GlobeNewsWire

Venus Concept Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TORONTO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has issued a stoc...

3 months ago - GlobeNewsWire

Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. He...

3 months ago - GlobeNewsWire

Venus Concept Announces Updated Release Date of November 10, 2022 for Third Quarter of Fiscal Year 2022 Financial Results

TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it is updating the r...

4 months ago - GlobeNewsWire

Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that Rajiv De Silva has b...

4 months ago - GlobeNewsWire

Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates

Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three...

6 months ago - GlobeNewsWire

Venus Concept to Release Second Quarter of Fiscal Year 2022 Financial Results on August 12, 2022

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fi...

7 months ago - GlobeNewsWire

Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates

Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Venus Concept Announces First Quarter of Fiscal Year 2022 Financial Results; Reaffirms Fiscal Year 2022 Revenue Guidance

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three ...

9 months ago - GlobeNewsWire

Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX

Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 Watts Clearance Expands Indications for Use to Include Non-Inv...

9 months ago - GlobeNewsWire

Venus Concept Announces First Patient Treatment in Study Evaluating the Safety and Efficacy of Aime™ Next Generation Robotic Technology for the Treatment of Moderate to Severe Facial Wrinkles

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that the first patient h...

9 months ago - GlobeNewsWire

Venus Concept to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022

TORONTO, April 04, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fi...

10 months ago - GlobeNewsWire

Venus Concept Submits FDA 510(k) Related to the Use of its Aime™ Next Generation Robotic Technology for Tissue Excision and Skin Resurfacing

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced it has submitted a 510(k...

10 months ago - GlobeNewsWire

Venus Concept (VERO) Reports Q4 Loss, Tops Revenue Estimates

Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Venus Concept Announces Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Revenue Guidance

TORONTO, March 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the thre...

10 months ago - GlobeNewsWire

Venus Concept Inc. to Present at the Maxim Virtual Growth Conference on March 28th

TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will pre...

11 months ago - GlobeNewsWire

Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16th

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will part...

1 year ago - GlobeNewsWire

Venus Concept to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 28, 2022

TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and f...

1 year ago - GlobeNewsWire

Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX for Non-Invasive Lipolysis of the Abdomen and Flanks, Cellulite Reduction and Muscle Conditioning

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received 510(...

1 year ago - GlobeNewsWire

Venus Concept Reports Preliminary Revenue Results for Fourth Quarter 2021

TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited reve...

1 year ago - GlobeNewsWire